Abivax
ABVX
38 hedge funds and large institutions have $372M invested in Abivax in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more capital invested
Capital invested by funds: $334M → $372M (+$37.5M)
7.5% more ownership
Funds ownership: 37.15% → 44.65% (+7.5%)
6% more funds holding
Funds holding: 36 → 38 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$70.9M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.45M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$4.63M |
| 4 |
ACM
Atika Capital Management
New York
|
+$1.73M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$8.74M |
| 2 |
Blackstone Inc
New York
|
-$3.65M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.68M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.38M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$924K |
ABVX Hedge Fund Activity: Q2 2024 in Review
38 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q2 2024, worth a combined $372M — up 11% from $334M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ABVX positions and 2 closed out — a net gain of 2 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was TCG Crossover Management, adding an estimated $70.9M. The largest seller was Commodore Capital, cutting an estimated $8.74M.
- 38 institutional investors held Abivax (ABVX) as of Q2 2024, up from 36 in Q1 2024.
- Funds reported $372M of Abivax stock for Q2 2024, up 11% quarter-over-quarter.
- 4 funds opened new Abivax positions in Q2 2024 and 2 closed out, a net change of +2 holders.
- The largest Abivax buyer in Q2 2024 was TCG Crossover Management, an estimated $70.9M added.
- The largest Abivax seller in Q2 2024 was Commodore Capital, an estimated $8.74M sold.
Based on aggregated 13F filings for Q2 2024.